UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
about
Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UseChemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsPharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRIGSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair arrayUGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Pattern recognition for predictive, preventive, and personalized medicine in cancer.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.On pharmacogenomics in pharmacy benefit management.UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
P2860
Q28068930-5DEE2480-A80A-422D-B715-421071027249Q30318822-5357C6CF-1CAD-421F-818C-5DA1506720AFQ33427471-FA6370CD-3573-4335-8D22-6DA5C3513963Q33783293-DC280F39-012E-4F06-81A0-C16344E158FFQ34008793-2E1DBA9C-86E4-4159-91FB-2A52F79D9C9FQ34391234-A261D497-CC5A-4EE3-A454-728EC90F48C0Q34467460-628A96F5-B92D-4262-ACAD-27597BE6BE0DQ34565071-35F7193E-CAA7-4503-B1E0-52B8B4933DBFQ34629650-F1224CC7-122C-403B-A0E2-3FBDD620CEFCQ35903844-B4C79D1D-FF80-4172-94F2-BAC07B850BE4Q36943992-F2CF0915-197D-4D37-99BD-B49ECA4E871AQ37287450-80356A04-9245-4FF5-A193-5602A18278AAQ37402459-3EAFA0D9-D438-428C-84A9-C94E80E6FFF7Q37575709-7C5BF705-1191-41BF-85E3-DDC8C2360185Q37682812-F9B88EEF-F76E-4BAA-84C3-045EC630471BQ37712297-17B1A378-C479-4884-955A-7EB1311A097AQ37726433-47035A7E-EB95-42E5-9365-2DF089A55F53Q37876401-9685979B-746C-40AC-967F-E6C6F9DBB2E9Q37887337-21067485-B841-4D7D-8D5B-4A0F56B99538Q38016943-7EA025DB-6BDD-4603-B274-6567F696FBB9Q38202816-2BE03EB9-D2D2-42B7-928F-4B650F03EF01Q38393997-E3929A08-B37B-497C-AD77-A0BDB8A6E09EQ38670423-42B0A3AF-3F52-4A08-8DCE-2BB3B99DE23BQ39566084-D7E80CC4-FC1A-4EDF-8160-715120A51B7FQ39644558-8C7EFD54-9B67-444B-9976-F84AD44C9795Q46007462-D1F286B9-149F-477E-82E3-780EB26FF0F5
P2860
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
UGT1A1*28 genotype and irinote ...... Colorectal Cancer Group study.
@en
type
label
UGT1A1*28 genotype and irinote ...... Colorectal Cancer Group study.
@en
prefLabel
UGT1A1*28 genotype and irinote ...... Colorectal Cancer Group study.
@en
P2093
P2860
P356
P1476
UGT1A1*28 genotype and irinote ...... Colorectal Cancer Group study
@en
P2093
C J A Punt
D M Kweekel
Dutch Colorectal Cancer Group study
H Gelderblom
N F Antonini
T Van der Straaten
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604461
P407
P577
2008-07-01T00:00:00Z